Cardiovascular Diabetology - Endocrinology Reports features a Collection on "Pleiotropic Actions of Incretin-Based Therapies". This is a companion Collection with Cardiovascular Diabetology with the title "Incretin-Based Therapies in Type 2 Diabetes and Obesity: Current Evidence and the Evolving Cardiometabolic Landscape".

Incretins play a crucial role in regulating glucose homeostasis and body energetics, and incretin based-therapies have fundamentally changed the management of people with diabetes and obesity. Importantly, recent evidence has revealed a wider profile of multi-organ beneficial effects for incretin therapies, including cardiovascular and renal protection, beyond glycaemic control. Whilst the full range of pleiotropic, organ-specific effects of incretins is still being elucidated, it should be noted that their use is limited by adverse events, such as gastrointestinal intolerance, and safety concerns regarding retinal disorders, muscle impairment, and pancreatitis.

Ongoing areas of interest include, but are not limited to:

• Tissue-specific effects of incretin-based medications
• Exploration of novel clinical indications for incretin therapies
• Safety concerns related to incretin therapies
• Next-generation incretin medications
• Combination of incretin treatment with lifestyle interventions

This Collection invites mini reviews, short reports and commentaries of clinical studies related to the pleiotropic effects of incretin-based therapies, but also welcomes original clinical, translation and basic research articles and reviews.

This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.

All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.

Cardiovascular Diabetology - Endrocrinology Reports features a Collection on "Endocrine Drivers and Clinical Implications of the Cardiovascular–Kidney–Metabolic Syndrome". This is a companion Collection with Cardiovascular Diabetology with the title "Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Risk Stratification, Prognostic Implications and Therapeutic Innovation" and with BMC Cardiovascular Disorders with the title "Cardiovascular-Kidney-Metabolic (CKM) Syndrome: diagnosis and management of a systemic disorder".

This Collection explores the endocrine dimensions of the cardiovascular–kidney–metabolic (CKM) syndrome and related disorders. CKM syndrome reflects the complex, multidirectional interactions among excess adiposity, metabolic dysfunction, endocrine abnormalities, chronic kidney disease, and cardiovascular injury. Given the endocrine system’s central role in metabolic and cardiovascular homeostasis, a deeper mechanistic and clinical understanding of endocrine factors — ranging from thyroid, adrenal, and pituitary function to bone metabolism, reproductive endocrinology, and neuroendocrine signaling — is important for advancing integrated risk stratification and therapeutic innovation across the CKM spectrum.

Possible topics of interest include:

• Endocrine determinants and modulators of CKM risk, including thyroid, adrenal, pituitary, reproductive, bone, and neuroendocrine disorders
• Life-course endocrine influences, such as childhood obesity, pubertal development, gestational diabetes, and pregnancy-associated endocrine conditions
• Biomarkers and diagnostic tools for early detection of multiorgan dysfunction across CKM stages, including endocrine-specific laboratory markers and advanced imaging
• Non-pharmacological multi-target interventions, including nutritional, behavioral, and exercise-based strategies, with emphasis on endocrine-metabolic mechanisms
• Emerging pharmacotherapies, including SGLT2 inhibitors, GLP-1 receptor agonists, non-steroidal MRAs, incretin combinations, anti-inflammatory agents, and endocrine-targeted therapies
• Translational and basic science investigations into hormonal signaling pathways linking endocrine disorders with cardiovascular and renal dysfunction

This Collection supports and amplifies research related to SDG 3, Good Health and Wellbeing.

All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.